AZP-38XX

AZP-38XX is an **undisclosed peptide-based preclinical research series** from Amolyt Pharma for the treatment of **acromegaly**. Based on the provided context, it represents a small peptide discovery program rather than a single fully characterized clinical candidate, and no specific active ingredient name, molecular sequence, brand name, or validated biological target has been publicly disclosed. The program appears to be part of Amolyt Pharma's rare endocrine disease pipeline and, following Amolyt Pharma's acquisition, is associated with AstraZeneca. Because AZP-38XX remains an early research series, its precise mechanism of action, route, formulation, and final development candidate have not been publicly defined.

Other names

AZP-38XX peptide seriesAZP38XX peptide seriesAZP 38XX peptide series